At a time when unverified messages can quickly unsettle markets and morale, Zuventus Healthcare Limited has stepped forward to reassure its people and partners that the company remains firmly on track.
Responding to rumours suggesting a possible closure or rebranding, the pharmaceutical company issued a formal clarification categorically denying the claims. Zuventus said there has been no closure, suspension, or transfer of business assets, and emphasised that its field staff continues to work at full strength across the country. For employees, doctors, and distributors who rely on daily continuity, the message was clear: business is continuing as usual.
The company also addressed confusion arising from claims linking it to Zorvia Healthcare Limited, stating that it has no association or affiliation with any such entity. Zuventus described these reports as inaccurate and misleading, noting that they have caused unnecessary concern among stakeholders.
Founded in 2002, Zuventus Healthcare is a subsidiary of Emcure Pharmaceuticals, which is listed on the Bombay Stock Exchange and the National Stock Exchange. The company reiterated its long-standing commitment to developing, manufacturing, and marketing high-quality and affordable medicines, a mission closely tied to patient trust and access to care.
Zuventus said it is actively pursuing appropriate legal remedies to protect its goodwill and the interests of its stakeholders. With a diversified portfolio spanning cardiology, diabetology, gastroenterology, orthopaedics, pain management, and nutraceuticals, and supported by robust manufacturing standards and a growing field force, the company stressed that its focus remains on people; patients, healthcare providers and employees who form the backbone of its business.
